Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Evofosfamide · HAP-302, TH-302

Small molecule · Cytotoxic, directed at DNA · developed by Threshold Pharmaceuticals

Phase 1/2 Most advanced trial

1 Registered trials

What is Evofosfamide?

Evofosfamide is a hypoxia-activated prodrug that releases a DNA-alkylating cytotoxin in hypoxic tumor environments. The active moiety introduces intra- and inter-strand DNA crosslinks, inhibiting DNA replication and cell division, and inducing apoptosis. It is studied in metastatic prostate, head and neck, and pancreatic cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: HAP-302, TH-302
Drug type: Small molecule
Targets: DNA
Mechanism: Cytotoxic, directed at DNA
Pathways: DNA replication, apoptosis
Therapy area: Oncology
Developer: Threshold Pharmaceuticals
In trials of: AGEN
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 8A9RZ3HN8W

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06782555	Phase 1/2	Metastatic Prostate Cancer	Recruiting	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic CancerMetastatic Prostate Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z